Albany Molecular Research Intangible Assets

The latest intangible assets for AMRI is $170M as of June 2017. That compares with $120M in the prior-year period — up 43.9% year over year. Investors often review this figure alongside Albany Molecular Research's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMRI's intangible assets moved from $120M to $170M — a 43.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Albany Molecular Research's operating scale or balance-sheet position.

A intangible assets figure of $170M for AMRI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AMRI's intangible assets ($170M), review year-over-year change from $120M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.